Novo Nordisk (Ozempic) earnings were $14.1B for the trailing 12 months ending Dec 31, 2024, with 14.3% growth year over year. The latest NVO earnings report on Dec 31, 2024 announced Q4 2024 earnings of $3.9B, down 2.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NVO reported annual earnings of $14.1B, with 13.6% growth.
NVO past earnings growth
How has NVO's earnings growth performed historically?
Novo Nordisk (Ozempic) Earnings Reports & History FAQ
What were Novo Nordisk (Ozempic)'s earnings last quarter?
On NVO's earnings call on Invalid Date, Novo Nordisk (Ozempic) (NYSE: NVO) reported Q4 2024 earnings per share (EPS) of $0.88, up 21.26% year over year. Total NVO earnings for the quarter were $3.94 billion. In the same quarter last year, Novo Nordisk (Ozempic)'s earnings per share (EPS) was $0.73.
Is Novo Nordisk (Ozempic) profitable or losing money?
As of the last Novo Nordisk (Ozempic) earnings report, Novo Nordisk (Ozempic) is currently profitable. Novo Nordisk (Ozempic)'s net profit (also called net income) for the twelve months ending Dec 31, 2024 was $14.08 billion, a 13.61% increase year over year.
What was NVO's earnings growth in the past year?
As of Novo Nordisk (Ozempic)'s earnings date in Invalid Date, Novo Nordisk (Ozempic)'s earnings has grown 14.32% year over year. This is 2.5 percentage points higher than the US Biotechnology industry earnings growth rate of 11.81%. NVO earnings in the past year totalled $14.10 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.